Cargando…

Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy

INTRODUCTION: Prostate-specific antigen (PSA) testing is a widely accepted screening method for prostate cancer, but with low specificity at thresholds giving good sensitivity. Previous research identified four single nucleotide polymorphisms (SNPs) principally associated with circulating PSA levels...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilbert, Rebecca, Martin, Richard M., Evans, David M., Tilling, Kate, Davey Smith, George, Kemp, John P., Lane, J. Athene, Hamdy, Freddie C., Neal, David E., Donovan, Jenny L., Metcalfe, Chris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592274/ https://www.ncbi.nlm.nih.gov/pubmed/26431041 http://dx.doi.org/10.1371/journal.pone.0136735

Ejemplares similares

Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful?
por: Harrison, Sean, et al.
Publicado: (2016)

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
por: Gilbert, Rebecca, et al.
Publicado: (2018)

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
por: Young, Grace J, et al.
Publicado: (2017)

Evaluating best practice in informed consent discussions: a new method of evaluating information provision and patient understanding during trial recruitment consultations
por: Wade, Julia, et al.
Publicado: (2013)

Alcohol consumption and PSA-detected prostate cancer risk—A case-control nested in the ProtecT study
por: Zuccolo, Luisa, et al.
Publicado: (2013)

Understanding factors influencing questionnaire response rates to maximise retention in a long term complex intervention trial
por: Lane, Athene J, et al.
Publicado: (2011)

Do people who choose their treatment in a large randomised trial with parallel preference groups differ at baseline from those who agree to random treatment allocation? Results from the protect study
por: Mills, Nicola, et al.
Publicado: (2015)

Men’s knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study
por: Horwood, Jeremy P, et al.
Publicado: (2014)

Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case–control study
por: Gilbert, Rebecca, et al.
Publicado: (2014)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
por: Rosario, Derek J, et al.
Publicado: (2012)

Exploring treatment preferences facilitated recruitment to randomized controlled trials
por: Mills, Nicola, et al.
Publicado: (2011)

Addressing patient treatment preferences at trial recruitment
por: Mills, Nicola, et al.
Publicado: (2011)

Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
por: Thorn, Joanna C., et al.
Publicado: (2023)

Evaluation of source data verification in a multicentre cancer trial (PROTECT)
por: Lane, J Athene, et al.
Publicado: (2013)

Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial
por: Wade, Julia, et al.
Publicado: (2015)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
por: Wade, Julia, et al.
Publicado: (2015)

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen
por: Harrison, Sean, et al.
Publicado: (2020)

The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals
por: Avery, Kerry NL, et al.
Publicado: (2014)

Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial
por: Walsh, Eleanor I., et al.
Publicado: (2016)

Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP)
por: Merriel, Samuel William David, et al.
Publicado: (2017)

Effect of green tea and lycopene on the insulin-like growth factor system: the ProDiet randomized controlled trial
por: Biernacka, Kalina M., et al.
Publicado: (2019)

Associations between an Obesity Related Genetic Variant (FTO rs9939609) and Prostate Cancer Risk
por: Lewis, Sarah J., et al.
Publicado: (2010)

Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)
por: Williams, Naomi J, et al.
Publicado: (2015)

Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: Opportunities for lifestyle modification
por: Hackshaw-McGeagh, Lucy E, et al.
Publicado: (2015)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
por: Dimitropoulou, P, et al.
Publicado: (2011)

Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
por: Thorn, Joanna C, et al.
Publicado: (2016)

Recruiters to randomised trials can be trained to facilitate recruitment and informed consent by exploring patients’ treatment preferences
por: Mills, Nicola, et al.
Publicado: (2013)

Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial
por: Keeney, Edna, et al.
Publicado: (2022)

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial
por: Donovan, Jenny L., et al.
Publicado: (2018)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
por: Turner, E L, et al.
Publicado: (2014)

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial
por: Er, Vanessa, et al.
Publicado: (2017)

Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study
por: Bryant, Richard J., et al.
Publicado: (2015)

Optimal PSA Threshold for Obtaining MRI-Fusion Biopsy in Biopsy-Naïve Patients
por: Wang, Luke L., et al.
Publicado: (2021)

Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study
por: Metcalfe, C, et al.
Publicado: (2009)

Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening
por: Pashayan, N, et al.
Publicado: (2009)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study
por: Catto, J W F, et al.
Publicado: (2011)

A predictive model for prostate cancer incorporating PSA molecular forms and age
por: Oto, Julia, et al.
Publicado: (2020)

Does prostate-specific antigen (PSA) mass or free PSA mass improve the accuracy of predicting total prostate volume in relation to obesity in men with biopsy-proven benign prostatic hyperplasia?
por: Jung, Jin-Woo, et al.
Publicado: (2019)

Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result
por: Macefield, R C, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2f1uhv2otu6cnf78grmbr6omnp